Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ecancermedicalscience ; 15: 1187, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33777180

RESUMO

The COVID-19 pandemic poses an unprecedented health crisis in all socio-economic regions across the globe. While the pandemic has had a profound impact on access to and delivery of health care by all services, it has been particularly disruptive for the care of patients with life-threatening noncommunicable diseases (NCDs) such as the treatment of children and young people with cancer. The reduction in child mortality from preventable causes over the last 50 years has seen childhood cancer emerge as a major unmet health care need. Whilst survival rates of 85% have been achieved in high income countries, this has not yet been translated into similar outcomes for children with cancer in resource-limited settings where survival averages 30%. Launched in 2018, by the World Health Organization (WHO), the Global Initiative for Childhood Cancer (GICC) is a pivotal effort by the international community to achieve at least 60% survival for children with cancer by 2030. The WHO GICC is already making an impact in many countries but the disruption of cancer care during the COVID-19 pandemic threatens to set back this global effort to improve the outcome for children with cancer, wherever they may live. As representatives of the global community committed to fostering the goals of the GICC, we applaud the WHO response to the COVID-19 pandemic, in particular we support the WHO's call to ensure the needs of patients with life threatening NCDs including cancer are not compromised during the pandemic. Here, as collaborative partners in the GICC, we highlight specific areas of focus that need to be addressed to ensure the immediate care of children and adolescents with cancer is not disrupted during the pandemic; and measures to sustain the development of cancer care so the long-term goals of the GICC are not lost during this global health crisis.

2.
Lancet Oncol ; 21(4): e185-e224, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32240612

RESUMO

We estimate that there will be 13·7 million new cases of childhood cancer globally between 2020 and 2050. At current levels of health system performance (including access and referral), 6·1 million (44·9%) of these children will be undiagnosed. Between 2020 and 2050, 11·1 million children will die from cancer if no additional investments are made to improve access to health-care services or childhood cancer treatment. Of this total, 9·3 million children (84·1%) will be in low-income and lower-middle-income countries. This burden could be vastly reduced with new funding to scale up cost-effective interventions. Simultaneous comprehensive scale-up of interventions could avert 6·2 million deaths in children with cancer in this period, more than half (56·1%) of the total number of deaths otherwise projected. Taking excess mortality risk into consideration, this reduction in the number of deaths is projected to produce a gain of 318 million life-years. In addition, the global lifetime productivity gains of US$2580 billion in 2020-50 would be four times greater than the cumulative treatment costs of $594 billion, producing a net benefit of $1986 billion on the global investment: a net return of $3 for every $1 invested. In sum, the burden of childhood cancer, which has been grossly underestimated in the past, can be effectively diminished to realise massive health and economic benefits and to avert millions of needless deaths.


Assuntos
Países em Desenvolvimento , Custos de Cuidados de Saúde , Acessibilidade aos Serviços de Saúde/organização & administração , Neoplasias/epidemiologia , Neoplasias/terapia , Criança , Efeitos Psicossociais da Doença , Humanos
3.
Lancet Oncol ; 18(11): e653-e706, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-29208398

RESUMO

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.


Assuntos
Pesquisa Biomédica/tendências , Planejamento em Saúde/tendências , Prioridades em Saúde , National Cancer Institute (U.S.)/tendências , Neoplasias/terapia , Pesquisa Biomédica/métodos , Previsões , Humanos , Oncologia/tendências , Neoplasias/diagnóstico , Medicina de Precisão/tendências , Estados Unidos
4.
Front Pediatr ; 4: 22, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27047905

RESUMO

Limited research exists regarding the most aggressive forms of hepatoblastoma. Cell lines of the rare subtypes of hepatoblastoma with poor prognosis are not only difficult to attain but also challenging to characterize histologically. A community-driven approach to educating parents and families, regarding the need for donated tissue, is necessary for scientists to have access to resources for murine models and drug discovery. Herein, we describe the currently available resources, existing gaps in research, and the path to move forward for uniform cure of hepatoblastoma.

5.
Curr Opin Pharmacol ; 3(3): 309-16, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12810198

RESUMO

Parallel technologies are emerging for the study of DNA (single nucleotide polymorphism genotyping and association studies), and RNA (microarrays and expression profiling). Muscle tissue has many intrinsic features that make it the tissue of choice to model the application of these newly emerging technologies. Well-preserved human biopsies are readily available both from volunteers undergoing specific muscle training protocols and from neuromuscular disease patients. Furthermore, the rapid adaptation of muscle to environmental cues (e.g. exercise, conditioning and weightlessness) makes it possible to conduct time series data in humans (molecular cause and effect). Muscle is also important in drug metabolism and adverse events, and the application of single nucleotide polymorphism association studies in muscle pharmacogenomics is a field of expected future growth.


Assuntos
Perfilação da Expressão Gênica , Músculo Esquelético/efeitos dos fármacos , Doenças Musculares/tratamento farmacológico , Doenças Musculares/genética , Desenho de Fármacos , Tratamento Farmacológico , Humanos , Músculo Esquelético/metabolismo , Atrofia Muscular/tratamento farmacológico , Atrofia Muscular/genética , Atrofia Muscular/metabolismo , Doenças Musculares/metabolismo , Distrofias Musculares/tratamento farmacológico , Distrofias Musculares/genética , Distrofias Musculares/metabolismo , Miosite/tratamento farmacológico , Miosite/genética , Miosite/metabolismo , Farmacogenética , Regeneração
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...